|
Patent landscape, scope, and claims summary: |
Comprehensive claim and US patent landscape analysis for U.S. Patent No. 10,071,953 (Formula II nitro-substituted anilide/benzoic-acid derivatives)
What is U.S. Patent 10,071,953 claiming: Formula (II) nitro compounds and combination compositions
U.S. Patent 10,071,953 is claim-driven around (i) a broad chemical genus defined by Formula (II) with a nitro substituent constraint, (ii) a narrow carveout to a specific named compound, and (iii) pharmaceutical compositions that optionally combine the claimed compound(s) with a broad list of therapeutic agents.
Claim 1 core scope: “A compound of Formula (II) or a salt”
Independent claim 1 covers:
- A compound represented by Formula (II) or a pharmaceutically acceptable salt, with a structural requirement that R³ = nitro.
- Two substituent positions, R⁴ and R⁵, each independently selected from a defined set that includes:
- Small substituents: H and C1–C6 alkyl
- Lipophilic/halogenated variants: haloalkyl, halogen
- Nitrile: –CN
- Alkoxy: C1–C6 alkoxy
- Acid/hetero-functional groups including: –C(=O)H, –C(=O)OH, –C(=O)–(C1–C6 alkyl) (aldehyde, carboxylic acid, acyl/ester-like carbonyl functionality as written)
- Sulfonic acid: SO3H
Material implication: the claim is a genus claim with:
- one fixed pharmacophore feature (nitro at R³),
- a broad combinatorial allowance for two additional substitution points (R⁴/R⁵ each independently chosen from a relatively large substituent set).
From an infringement perspective, the easiest route for a challenger is to argue that a competitor’s molecule does not satisfy:
- the nitro constraint at the specific R³ position, or
- one of the R⁴/R⁵ allowable substituent classes at the required attachment points.
From a validity perspective, the genus breadth is high enough to raise typical issues:
- enablement and written description if the specification’s working examples are sparse versus the full breadth permitted by R⁴/R⁵ permutations,
- obviousness depending on how many prior-art analogs exist with similar substitution patterns.
Claims 2 and 3: tightening R⁴ and R⁵ to a smaller set
Claims 2 and 3 depend on claim 1 and restrict the substituent sets for R⁴ and R⁵, respectively, to:
- H, methyl, tert-butyl, methoxy,
- fluoro, chloro, bromo, trifluoromethyl,
- acetyl.
Material implication: these are narrower embodiments of the genus. They matter for:
- claim charting against specific marketed or preclinical analogs,
- partial invalidity strategies where an invalidity attack lands against the broader R⁴/R⁵ definitions but leaves narrower subsets potentially enforceable.
Claims 4 and 7: composition-of-claim + carrier
- Claim 4: pharmaceutical composition comprising at least one compound of claim 1 plus a pharmaceutically acceptable carrier.
- Claim 7: same structure but limited to the specific compound of claim 6.
Material implication: these are straightforward formulation claims. They are typically less vulnerable on novelty if the carrier and composition are generic, but can be strong if the claimed compound is not otherwise covered by other composition patents in the estate or if the compound is not disclosed in earlier art in a way that enables formulation use.
Claims 5 and 8: combination compositions including broad “therapeutic agent” lists
Material implication: the combination scope is extremely broad because:
- it does not tie the therapeutic agent to a specific indication, mechanism, dosing ratio, or sequence of administration,
- it reads on “any mixture” with listed agents without requiring a synergistic treatment recitation.
This breadth increases two legal risks for enforceability:
- Anticipation/obviousness: if prior art disclosed the claimed nitro-substituted scaffold in a combination context with any of these commonly used agents, the combination limitation may not add patentable distinction.
- Indefiniteness / overbreadth pressure: very broad therapeutic-agent language can be argued as an attempt to claim an extensive field without a specific technical relationship.
At the same time, it can be enforced strongly where:
- the combination claim is used against a party marketing a specific fixed combination regimen including a listed agent and the claimed compound.
What specific compound is claim 6, and how does it affect the patent’s infringement and validity posture?
Claim 6 fixes a single chemical identity:
- 3-((4-nitronaphthalen-1-yl)amino)benzoic acid or a salt.
Key effect:
- A single-compound claim can be attacked with targeted prior art searches for this exact molecule and salts, which is often easier than invalidating a full genus.
- If that compound is not disclosed pre-filing, claim 6 can provide a clean fallback even if genus coverage is attacked.
In infringement terms:
- A competitor that makes or sells a compound that matches claim 6 (the named structure or salt) risks direct infringement of claim 6, claim 7 (composition), and claim 8 (combination composition), regardless of whether it fits claim 1’s broader Formula (II) framework.
How broad is the genus (Formula II) in practice, and what does that mean for “how many patents cover” related chemistry?
Even without the full text of Formula (II) substituent positions and ring connectivity, the claim language shows the breadth pattern:
- one required nitro at R³,
- two independently variable substituents at R⁴ and R⁵,
- broad ranges for salts.
That combination typically generates a large number of possible analogs:
- each of R⁴ and R⁵ can take multiple functional classes (H, alkyl, haloalkyl, halogen, CN, alkoxy, carbonyl-containing groups, and SO3H).
- the resulting chemical space is large enough that a competitor can often design around by:
- removing nitro,
- moving nitro to a different position,
- using substituents outside the enumerated sets at either R⁴ or R⁵.
Critical business point: if U.S. 10,071,953 is part of a larger continuation family, related claims may exist that cover:
- alternate nitro placements,
- alternate substituent definitions for R⁴/R⁵,
- alternate salts,
- different ring systems that can capture “design-around” analogs.
However, with only the provided claims excerpt, the exact family breadth and overlap across other US patents cannot be established here.
When does the exclusivity end for U.S. 10,071,953, and does it track FDA approval timelines?
No FDA product tie-up is provided in the prompt. Exclusivity and Orange Book timelines depend on:
- the NDA/BLA referenced,
- the specific marketing status,
- patent listing type (drug substance vs drug product vs method-of-use),
- regulatory exclusivity (NCE, new indication, pediatric, etc.).
With no linkage to the drug, NDA/BLA number, or Orange Book listing, an exclusivity timetable cannot be produced from the information supplied.
What patent litigation or Paragraph IV risks attach to this estate?
Paragraph IV risks depend on:
- which Orange Book-listed patents map to the relevant NDA/BLA,
- which generic/BI/sponsor filed challenges,
- the parties and case numbers.
No litigation or Orange Book mapping data is included in the prompt. Without those identifiers, it is not possible to produce an accurate litigation landscape for this specific US patent.
What formulations and combination regimens are potentially protected?
Protected formulation category
- Generic composition: claim 4 and claim 7 are “compound + pharmaceutically acceptable carrier” with no other constraints. This can capture:
- tablets, capsules, injectables, suspensions, topical formulations if technically feasible for the compound and carrier, subject to the claim not being limited by route in the unavailable full claim set.
- Combination category: claim 5 and claim 8 can cover at least two-drug regimens:
- the claimed compound plus one or more listed agents, including cancer therapies (docetaxel, bevacizumab, cabazitaxel), hormonal therapies (tamoxifen, anastrozole, letrozole, etc.), and other anti-inflammatory/epigenetic agents (indomethacin, SAHA).
Critical limit
The excerpt does not show:
- route restrictions,
- dosing ratios,
- frequency or co-administration requirements,
- a mechanistic or therapeutic rationale.
That omission has two downstream effects:
- it makes non-infringement design-around more dependent on chemical identity (did you use the claimed compound?) than on regimen mechanics (how did you dose it?),
- it also raises enforceability pressure if a defendant argues the combination claim is too broad relative to disclosed support.
How strong is the patent estate for this chemistry, and where are the highest-risk claim vulnerabilities?
Using only the claim-set structure provided:
Highest-risk axis: genus breadth (claim 1) versus disclosure support
- Claim 1’s enumerated R⁴/R⁵ sets generate a broad genus.
- If the specification does not provide enough representative examples across the full substitution range (including key functional classes like aldehyde/carboxylic acid/sulfonic acid), invalidity arguments based on written description and enablement are typical.
Moderate-risk axis: combination language (claims 5 and 8)
- Combination with a long list of therapeutic agents without indication/mechanism constraints often faces:
- obviousness attacks (known combination therapy plus substitution),
- anticipation if any prior disclosure contains the same compound combined with one of the listed agents in a therapeutic context.
Potential strength axis: claim 6 (specific compound)
- A specific compound claim is often more defensible because:
- exact-match prior art must be found to fully anticipate,
- it is a narrower target for invalidity attacks.
Design-around reality
Competitors can often avoid infringement by:
- not incorporating the nitro substituent at the specified R³ position,
- substituting at the R⁴/R⁵ positions with groups not in the enumerated sets.
That reduces practical enforceability of the genus unless the competitor stays within the claim’s substitution classes.
What would a credible generic entry risk look like for this patent?
A credible risk assessment requires:
- Orange Book listing for U.S. 10,071,953,
- whether the generic product includes the same nitro-substituted scaffold or the specific claim 6 compound,
- whether the proposed label includes any listed therapeutic agent combinations,
- whether the generic filing is Abbreviated New Drug Application (505(j)) or a biosimilar pathway (not applicable for small molecule patents unless biologics are part of combination product regimens).
No such regulatory and product data is present in the prompt, so a generic entry scenario cannot be accurately constructed.
Key Takeaways
- U.S. Patent 10,071,953 is structured as a genus chemical patent (Formula II) anchored on R³ = nitro, with two substitution positions R⁴ and R⁵ spanning broad functional classes, plus composition-of-that-compound claims.
- The patent has a specific “fallback” in claim 6 covering 3-((4-nitronaphthalen-1-yl)amino)benzoic acid (and salts), which is narrower and often easier to assess for exact-match infringement and validity.
- The combination claims (claims 5 and 8) are broad “compound + listed therapeutic agent(s)” without indication, dosing, or mechanistic constraints, which can increase obviousness and enforceability challenges while keeping infringement tied mainly to chemical identity and marketing of the combination regimen.
- A complete US landscape analysis for exclusivity, Orange Book status, Paragraph IV filings, and litigation cannot be derived from the excerpt alone because the needed NDA/BLA linkage, listing codes, assignees, and case docket identifiers are not provided.
FAQs
-
Can a competitor avoid claim 1 by changing the nitro position or removing nitro entirely?
The claim requires R³ = nitro as written, so noncompliance with that structural constraint is a primary design-around route.
-
Does claim 6 create independent infringement exposure even if a product falls outside claim 1’s Formula (II)?
Yes. Claim 6 covers a specific compound identity, so a product matching claim 6 can infringe claim 6 and its dependent composition/combination claims even if it does not meet claim 1’s broader Formula (II) constraints.
-
Do claims 5 and 8 require a specific indication or dosing regimen?
The provided claim text lists therapeutic agents but does not impose indication or dosing constraints. Enforceability and validity still depend on the rest of the full specification and the litigation record, but the excerpt itself does not narrow the regimen.
-
Are salts separately covered?
Yes. Claim 1 and claim 6 each include “or a salt thereof,” and the composition claims cover compositions comprising those compounds and carriers.
-
What is the most likely invalidity attack surface for this patent based on the claim structure?
The broadness of claim 1’s combinatorial substituent definitions (R⁴/R⁵) and the breadth of claims 5 and 8’s therapeutic-agent combination list are the primary practical axes for written description/enablement and obviousness-type challenges.
References
- U.S. Patent No. 10,071,953. Claims provided in prompt (Claims 1–8).
More… ↓
⤷ Start Trial
|
